Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

PURPOSE: We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with recurrent or metastatic SCCHN wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Argiris, Athanassios, Ghebremichael, Musie, Gilbert, Jill, Lee, Ju-Whei, Sachidanandam, Kamakshi, Kolesar, Jill M., Burtness, Barbara, Forastiere, Arlene A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3612594/
https://ncbi.nlm.nih.gov/pubmed/23460714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.4272
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados